P Pharming Group NV
P
Uždarymo kaina
1.1 -2.57
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
1.096
Max
1.133
Pajamos | -10M -5.1M |
|---|---|
Pardavimai | -36M 71M |
P/E Sektoriaus vid. | 55.3 51.415 |
Pelnas, tenkantis vienai akcijai | 0.01 |
Pelno marža | -7.196 |
Darbuotojai | 407 |
EBITDA | -4.8M -2.1M |
Kitas uždarbis | 2026-07-30 |
|---|
Rinkos kapitalizacija | -227M 781M |
|---|---|
Ankstesnė atidarymo kaina | 3.67 |
Ankstesnė uždarymo kaina | 1.1 |
Pharming Group NV Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Susijusios naujienos
Akcijų palyginimas
Kainos pokytis
Pharming Group NV Prognozė
Finansinės naujienos
Pardavimo ir administravimo išlaidos
Veiklos sąnaudos
Ikimokestinis pelnas
Pardavimai
Pardavimo savikaina
Bendrasis pelnas iš pardavimo
Skolų palūkanų išlaidos
EBITDA
Veiklos pelnas
$
Apie bendrovę Pharming Group NV
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K" inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.
